Effect of [Cu(4,7-dimethyl-1,10-phenanthroline)(acetylacetonato)]NO3, Casiopeína III-Ea, on the activity of cytochrome P450.

Casiopeína III-Ea (Cas III-Ea(1)) is a copper complex with antiproliferative and antitumor activities, designed to act via alternative mechanisms of action different from Cisplatin. This compound has also been well characterized in preclinical test and pharmacokinetic analysis, being a good candidate for clinical phases. Since very little is known about the processes of biotransformation of therapeutic metal based drugs, this paper report the first approach to the study of the interaction between metal complex Cas III-Ea and cytochromes P450 with the aim to find out possible biotransformation pathways for this complexes and feasible drug-drug interactions. Results showed that Cas III-Ea is a strong irreversible competitive inhibitor of CYP1A1 (IC50 = 7.5 ± 1.0 µM; Ki = 240 nM). The magnitude of values indicate that it is necessary to be taken into account such effect when analyzing possible drug interactions with these new drugs in order to prevent adverse reactions derived from this inhibition.

Mutagenic and antimutagenic effects of Heterotheca inuloides.

The antioxidant and hepatoprotective effects of Heterotheca inuloides have been reported before, nevertheless its use as a possible chemopreventive agent has not been documented. The aim of this study was to evaluate the mutagenic and antimutagenic activities of H. inuloides extracts using the Ames test. Both, the methanolic and acetonic extracts, were mutagenic in the TA98 but not in TA100 or TA102 strains. On the other hand, the methanolic extract reduced the mutagenicity of norfloxacin, benzo[a]pyrene and 2-aminoanthracene. Quercetin, one of the main components in the methanolic extract, also presented a mutagenic/antimutagenic dual effect and is an inhibitor of Cytochrome P450 (CYP) 1A. The antigenotoxic properties of H. inuloides could be due to the antioxidant properties previously reported and to its CYP inhibitory effect mediated by quercetin. Further studies with in vivo systems will afford information about H. inuloides beneficial and detrimental properties.

CYP1A1 and Cnr nitroreductase bioactivated niclosamide in vitro.

Niclosamide produces genotoxic effects, such as point mutations in Salmonella sp., sperm-head abnormalities in mice and clastogenic effects in human lymphocytes in vitro and in vivo. As cytochrome P450 could be involved in the bioactivation of niclosamide, we investigated which subfamily was involved. We used liver microsomal fractions from rats treated with phenobarbital/ß-naphthoflavone (PB/ß-NF), benzo[a]pyrene (BaP) or cyclohexanol, which are known to induce different cytochrome P450 subfamilies, such as CYP2B, CYP1A1, CYP1A2 and CYP2E1. We also inhibited CYP1A and CYP2E using α-NF and diethyldithiocarbamate to identify the cytochrome P450 involved. Liver-S9 fractions obtained from PB/ß-NF- and BaP-treated rats significantly increased the number of revertants induced by niclosamide, while the CYP1A1 inhibitor α-NF decreased the number of revertants. The incubation of niclosamide with CYP1A1 Supersomes™ increased the number of revertants, suggesting that CYP1A1 is responsible for the bioactivation of niclosamide. Nitroreduction is also involved in niclosamide bioactivation, as the nitroreductase-deficient strain YG7132 did not respond to the niclosamide treatment. Our findings indicated that a metabolite, derived from the action of CYP1A1 and a nitroreduction-reaction process, has a key role in the bioactivation of niclosamide.

[In vitro evaluation of the chemopreventive potential of saffron]. / Evaluación in vitro del potencial quimiopreventivo del azafrán.

UNLABELLED: Cancer is a very important national health problem in Mexico, while a significant increase in the total and childhood cancer mortality has been recorded during the last decades. Chemoprevention, defined as the use of natural or synthetic agents to prevent or to block the development of cancer in human beings, is a new and promising strategy in the battle against cancer. Saffron, obtained from the dried red-dark stigmas of Crocus sativus L., an important spice rich in carotenoids, is commonly consumed in different parts of the world and used as a medical drug to treat numerous diseases. OBJECTIVE: To test the toxicity of saffron extract in vivo; to separate different ingredients in saffron extracts; to examine the cytotoxic effect of saffron and its main components on the growth of different human malignant cells in vitro; to evaluate the mutagenic and antimutagenic activities of saffron extract. METHODS: HPLC with photodiode-array detection was used for semi-preparative separation of different ingredients of saffron crude extract. Colony formation assay was used to determinate the cytotoxic activity of saffron extract and its components on human tumor cells in vitro. Mutagenicity and antimutagenicity assays were performed by the Ames method. RESULTS: Saffron is not toxic, non-mutagenic, non-antimutagenic and non-comutagenic. Twelve components were isolated: crocin-1, crocin-2, crocin-3, picrocroein, acid form of picrocrocin, HTCC-diglycosil-kaempferol trans-crocin-4, trans-crocin-2, trans-crocin-3, safranal, crocetin and cis-crocin-3. Saffron extract itself and some of its ingredients displayed a dose-dependent inhibitory activity against different types of human malignant cells in vitro. HeLa cells were more susceptible to saffron than other tested cells. CONCLUSIONS: Taken together, our results and literature data indicate that saffron could be used as a potential cancer chemopreventive agent in clinical trials.